ATE392207T1 - Zusammensetzung und verfahren zur verwendung bei darmreinigungsverfahren - Google Patents

Zusammensetzung und verfahren zur verwendung bei darmreinigungsverfahren

Info

Publication number
ATE392207T1
ATE392207T1 AT03795536T AT03795536T ATE392207T1 AT E392207 T1 ATE392207 T1 AT E392207T1 AT 03795536 T AT03795536 T AT 03795536T AT 03795536 T AT03795536 T AT 03795536T AT E392207 T1 ATE392207 T1 AT E392207T1
Authority
AT
Austria
Prior art keywords
composition
procedures
patients
mmol
blood glucose
Prior art date
Application number
AT03795536T
Other languages
English (en)
Inventor
Mats Lake
Ulf Smith
Mette Axelsen
Eva Olausson
Original Assignee
Metcon Medicin Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202723A external-priority patent/SE0202723D0/xx
Application filed by Metcon Medicin Ab filed Critical Metcon Medicin Ab
Application granted granted Critical
Publication of ATE392207T1 publication Critical patent/ATE392207T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03795536T 2002-09-13 2003-09-12 Zusammensetzung und verfahren zur verwendung bei darmreinigungsverfahren ATE392207T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202723A SE0202723D0 (sv) 2002-09-13 2002-09-13 Composition and method for use in intestinal cleansing procedures
US42532002P 2002-11-12 2002-11-12

Publications (1)

Publication Number Publication Date
ATE392207T1 true ATE392207T1 (de) 2008-05-15

Family

ID=31996343

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03795536T ATE392207T1 (de) 2002-09-13 2003-09-12 Zusammensetzung und verfahren zur verwendung bei darmreinigungsverfahren

Country Status (7)

Country Link
US (1) US20050054611A1 (de)
EP (1) EP1545563B1 (de)
JP (1) JP2006506349A (de)
AT (1) ATE392207T1 (de)
AU (1) AU2003259006A1 (de)
DE (1) DE60320429D1 (de)
WO (1) WO2004024168A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176113A1 (en) * 2009-06-03 2011-12-29 Axcan Pharma Inc L-sugar colon cleansing agent and uses thereof
WO2012046847A1 (ja) * 2010-10-08 2012-04-12 味の素株式会社 Ｃｔコロノグラフィに用いられる経口投与用液剤及び消化管造影用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1414121A (en) * 1971-09-15 1975-11-19 Smith W J Antacid composition and its preparation
DE3705874A1 (de) * 1987-02-24 1988-09-01 Laevosan Gmbh & Co Kg Darmspuelloesung
CA1338596C (en) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
CA2007387C (en) * 1990-01-09 1996-06-11 Isami Kimura Bowel lavage composition
SE469775B (sv) * 1990-12-21 1993-09-13 Ljungqvist Olle Medical Ab Dryck för preoperativ tillförsel innehållande en kolhydratblandning och användning av sackarider för framställning av drycken
IL112967A0 (en) * 1994-03-15 1995-06-29 Los Angeles Childrens Hospital Pharmaceutical compositions comprising a complex carbohydrate to diminish hypoglycemia in patients with diabetes mellitus
GB2311882B (en) * 1996-04-04 2000-08-09 Videologic Ltd A data processing management system
ATE201824T1 (de) * 1996-11-13 2001-06-15 Cb Fleet Co Inc Darmreiniger auf basis von umhülltem natriumphosphat
US6162464A (en) * 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
JPH11332514A (ja) * 1998-05-22 1999-12-07 Nof Corp バランス栄養食品
US6534487B1 (en) * 1999-08-03 2003-03-18 Childrens Hospital Los Angeles Methods for suppressing appetite and enhancing exercise and recovery
US6316427B1 (en) * 2000-04-04 2001-11-13 Metcon Medicin Ab Treatment for diabetes
CA2422900A1 (en) * 2000-10-25 2002-05-02 Metcon Medicin Ab New composition and method for the treatment of dysglucaemia

Also Published As

Publication number Publication date
EP1545563B1 (de) 2008-04-16
DE60320429D1 (de) 2008-05-29
JP2006506349A (ja) 2006-02-23
US20050054611A1 (en) 2005-03-10
AU2003259006A1 (en) 2004-04-30
WO2004024168A1 (en) 2004-03-25
EP1545563A1 (de) 2005-06-29
WO2004024168A8 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2007038623A3 (en) Oral formulation for enteric disorders and/or rehydration
CN103005057A (zh) 一种降血糖的保健茶及制备方法
Mulder et al. Renal function and renal disease in the elderly:: Part I
Keys et al. Experimental starvation in man
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CN107594520A (zh) 一种供痛风患者食用的配方食品
DE60320429D1 (de) Zusammensetzung und verfahren zur verwendung bei darmreinigungsverfahren
WO2004060316A3 (en) Irs modulators
Kolls et al. Contributions to the pharmacology of extracts of the posterior lobe of the pituitary gland
CN105941562A (zh) 一种防治高血糖的保健饼干
JP5158779B2 (ja) Ｄ−アロースを有効成分とする血圧上昇抑制剤
BR0011714A (pt) Medicamento oftalmológico neuro-protetor e retino-protetor e utilização de um princìpio ativo de medicamento
WO2003011119A3 (en) Methods and compositions for diagnosis and treatment of vascular conditions
RU2058136C1 (ru) Способ лечения аллергических дерматозов
KR19980019494A (ko) 건강 뽕잎 분말
Yeomans et al. Azotemia in typhus fever
CN107212368A (zh) 一种降低血糖保健食品及其制备方法
Markova et al. The state of hemodynamics and microcirculation in patients with hypertensive disease during long term controlled therapy with lisinopril
RU2262926C1 (ru) Способ лечения диабетической ангио-ретинопатии
CN107865098A (zh) 一种益智健康的荞麦奶粉
PRESKORN Have You Phenotyped Your Patient Lately?
EP0778027A3 (de) Verwendung von Kieselerde zur Herstellung von Arzneimitteln
Robb-Nicholson By the way, doctor. A few months ago, I was surprised to read that a new study has raised a question about the value of screening mammograms. Is that true? I thought the importance of having such mammograms was well-established. I'm 52 and have been getting annual mammograms for 10 years. Should I stop?
Sommers et al. Dwelling, Chronically Ill Elders
Fever 444 MARCH 25, 1944 MEDICAL NEWS BRITISH

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties